Why It Matters

Teva Pharmaceuticals USA Inc. terminated its lobbying engagement with Talley Strategies LLC on August 31, according to a termination filing submitted September 4. The pharmaceutical company had retained the firm to handle drug pricing advocacy work through the middle of 2026.

While a discrete account, the termination represents a shift in how Teva manages its Capitol Hill presence at a firm that counted the pharmaceutical company among its active clients.

Teva has reported $5.43 million in lobbying expenses over the past four quarters and currently employs 11 active lobbyists across multiple firms. Teva Pharmaceuticals USA Inc. has worked with Capitol Hill Consulting Group, Faegre Drinker Biddle & Reath LLP, and David Melech Friedman on lobbying matters.

Teva Pharmaceuticals USA Inc. did not report a filing amount in its third-quarter 2026 termination filing with Talley Strategies LLC.

Broader Context

Teva's lobbying agenda through Talley Strategies focused on issues related to pharmaceutical drug pricing. The firm lobbied on Health Issues and Pharmacy categories during its time representing Teva but did not reference specific bills in its disclosures.

In the first quarter of 2019, Teva lobbied on multiple generic drug bills, including the Creating & Restoring Equal Access to Equivalent Samples Act, the Fast Generics Act, the Preserve Access to Affordable Generic & Biosimilars Act, and the Protecting Consumer Access to Generic Drugs Act. The company also tracked the BLOCKING Act, the Fair & Immediate Release of Generic Drugs Act, the Purple Book Continuity Act, the Orange Book Transparency Act, and the Hatch-Waxman Integrity Act during that period.

In the first quarter of 2026 and second quarter of 2026, Teva Pharmaceuticals USA Inc.'s lobbying disclosure reports filed on April 21 and July 20 listed no issues or legislation.

The Bottom Line

Teva continues to maintain a multi-firm lobbying operation even after shedding Talley Strategies. Amber Talley, the principal at Talley Strategies who handled the Teva account, brought experience with the House Oversight and Government Reform Committee and the Senate Special Committee on Aging from her prior congressional work. No specific legislation was targeted in Talley Strategies LLC's lobbying efforts for Teva Pharmaceuticals USA Inc.

Spot something wrong? Report an issue with this article